Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price target of p1,500.00. The company’s shares closed yesterday ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p2,610.00. The company’s shares opened today at p1,430.50.

BRENTFORD, Britain (AP) — BRENTFORD, Britain (AP) — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK said it bought the rights to the inventions when it acquired part of Novartis' vaccine business in 2015. [[nid:705778]] Healthcare COVID-19 Covid-19 vaccinations Lawsuits ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...